MXPA05012274A - Derivado de cianofluoropirrolidina. - Google Patents

Derivado de cianofluoropirrolidina.

Info

Publication number
MXPA05012274A
MXPA05012274A MXPA05012274A MXPA05012274A MXPA05012274A MX PA05012274 A MXPA05012274 A MX PA05012274A MX PA05012274 A MXPA05012274 A MX PA05012274A MX PA05012274 A MXPA05012274 A MX PA05012274A MX PA05012274 A MXPA05012274 A MX PA05012274A
Authority
MX
Mexico
Prior art keywords
cyanofluoropyrrolidine
compound
derivative
diseases
so2r5
Prior art date
Application number
MXPA05012274A
Other languages
English (en)
Inventor
Ayako Mikami
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MXPA05012274A publication Critical patent/MXPA05012274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Un compuesto de cianofluoropirrolidina representado por la siguiente formula (I) (ver formula (I)): (en donde A representa hidrogeno o fluor; R1 y R2 son los mismos que se definen en la descripcion; X representa un solo enlace o un grupo alquileno de C1-3; y R3 representa N(R4)COR5, -N(R4)SO2R5, etc.), una sal farmaceuticamente aceptable del compuesto, o un hidrato del compuesto; tambien son utiles como un agente preventivo o terapeutico para enfermedades o estados que pueden ser aliviados inhibiendo la dipeptidil peptidasa IV (DPPIV) y para diabetes, enfermedades inmunologicas, etc.
MXPA05012274A 2003-05-15 2004-05-17 Derivado de cianofluoropirrolidina. MXPA05012274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003137062 2003-05-15
PCT/JP2004/006983 WO2004101514A1 (ja) 2003-05-15 2004-05-17 シアノフルオロピロリジン誘導体

Publications (1)

Publication Number Publication Date
MXPA05012274A true MXPA05012274A (es) 2006-02-10

Family

ID=33447245

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012274A MXPA05012274A (es) 2003-05-15 2004-05-17 Derivado de cianofluoropirrolidina.

Country Status (11)

Country Link
US (1) US20060293297A1 (es)
EP (1) EP1627870A1 (es)
JP (1) JPWO2004101514A1 (es)
KR (1) KR20060009933A (es)
CN (1) CN1791575A (es)
AU (1) AU2004238719A1 (es)
CA (1) CA2525442A1 (es)
MX (1) MXPA05012274A (es)
NO (1) NO20055971L (es)
RU (1) RU2005139134A (es)
WO (1) WO2004101514A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005293266B2 (en) 2004-10-12 2011-09-29 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CL2007001011A1 (es) 2006-04-11 2008-05-16 Arena Pharm Inc Metodo para la identificacion de secretagogos de gip, polipeptido inhibidor gastrico; y uso de un receptor acoplado a proteina g para clasificar compuestos de prueba como secretagogos de gip.
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CN103804266B (zh) * 2014-02-21 2016-06-08 张家港威胜生物医药有限公司 一种维达列汀中间体的合成方法
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
CN108164528B (zh) * 2018-03-31 2019-03-22 杭州巴洛特生物科技有限公司 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JP2004026820A (ja) * 2002-05-09 2004-01-29 Taisho Pharmaceut Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤
WO2003095425A1 (fr) * 2002-05-09 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Derives de cyanopyrrolidine

Also Published As

Publication number Publication date
AU2004238719A1 (en) 2004-11-25
CN1791575A (zh) 2006-06-21
JPWO2004101514A1 (ja) 2006-07-13
EP1627870A1 (en) 2006-02-22
WO2004101514A1 (ja) 2004-11-25
US20060293297A1 (en) 2006-12-28
KR20060009933A (ko) 2006-02-01
CA2525442A1 (en) 2004-11-25
NO20055971L (no) 2005-12-15
RU2005139134A (ru) 2006-08-27

Similar Documents

Publication Publication Date Title
MXPA04003759A (es) Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv.
MXPA05012274A (es) Derivado de cianofluoropirrolidina.
TW200505919A (en) DPP-IV inhibitors
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
TW200732303A (en) Novel fused pyrrole derivatives
WO2004013120A8 (en) Novel benzodioxoles
GB0413087D0 (en) Therapeutic compounds
TW200745032A (en) Novel heterobicyclic derivatives
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
MX2007004302A (es) Inhibidores de pi3 cinasa gamma para el tratamiento de anemia.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2007003913A (es) Alquil-piridinas como inhibidores de 11 beta para diabetes.
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
NO20052182L (no) Nye forbindelser
TW200702330A (en) 3,4,5-Substituted piperidines
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200503712A (en) (2-carboxamido)(3-amino)thiophene compounds
MX2010001566A (es) Derivado de aminopirazolamida.
MX2009008756A (es) Compuesto macrociclico.
WO2007033039A3 (en) Proteasome inhibiting beta lactam compounds
DE602004018630D1 (en) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
GB0314967D0 (en) Piperazine derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal